COLOGNE, Germany, November 19, 2026
DISCO Pharmaceuticals has entered into a strategic collaboration and option-to-license agreement with AbbVie to discover and develop next-generation AND-gated bispecific therapeutics for solid tumors. The partnership combines DISCO’s proprietary DISCOtech® surfaceome mapping platform and tumor-selective bispecific discovery technology with AbbVie’s oncology research and development expertise. The collaboration aims to identify highly selective tumor-targeting therapies designed to improve cancer treatment precision while minimizing damage to healthy tissues. Under the agreement, DISCO will receive $40 million in upfront payments and is eligible to earn up to $2.5 billion in option, development, and other milestone payments, in addition to tiered royalties on worldwide net sales.
DISCOtech Platform Enables Tumor-Selective Target Discovery
The collaboration will leverage DISCO’s proprietary DISCOtech® platform, which systematically maps cell-surface protein expression patterns across cancer cells to identify tumor-associated target pairs. The technology supports the development of AND-gated bispecific therapeutics, which are designed to recognize two specific targets simultaneously on the same tumor cell. By requiring the presence of both molecular targets for effective binding, the approach aims to improve tumor specificity and potentially reduce on-target, off-tumor toxicity, a major challenge associated with targeting antigens that are also expressed in healthy tissues. DISCO’s discovery platform is intended to expand the range of cancer targets that can be therapeutically addressed, creating opportunities for highly selective treatment strategies across difficult-to-treat solid tumors.
AND-Gated Bispecifics Aim to Improve Precision Oncology
AND-gated therapeutics are engineered to recognize combinations of cell-surface targets rather than relying on a single antigen, potentially enabling more selective tumor-cell recognition. DISCO is developing this strategy across multiple therapeutic modalities, including antibody-drug conjugates (ADCs) and T-cell engagers, with the goal of delivering potent anti-tumor activity while broadening the therapeutic window. The approach could help address limitations of conventional targeted cancer therapies, particularly when individual tumor-associated targets are also present on normal cells. Through the collaboration, DISCO will conduct specified research activities to identify and advance selected programs, while AbbVie will have the option to exclusively license eligible programs for further development following completion of the agreed research milestones. The companies have not disclosed specific molecular targets or clinical-stage candidates arising from this collaboration.
Multi-Billion-Dollar Agreement Expands Oncology Pipeline
The agreement strengthens DISCO’s partnered research strategy and complements its internal pipeline of precision oncology programs. The company said its lead programs are progressing toward clinical development for small cell lung cancer and colorectal cancer, reflecting its broader focus on difficult-to-treat malignancies. The collaboration also highlights growing pharmaceutical industry interest in tumor-selective target discovery, bispecific antibody engineering, and next-generation precision medicines. By combining DISCO’s surfaceome mapping capabilities with AbbVie’s global drug-development expertise, the partnership seeks to translate novel tumor-targeting discoveries into potential therapeutic candidates for patients with significant unmet medical needs. The financial structure, including the $40 million upfront payment and up to $2.5 billion in potential milestone payments, underscores the strategic value of advancing differentiated bispecific approaches in oncology, although future payments will depend on research outcomes, option exercises, and development progress.
Source: DISCO Pharmaceuticals, AbbVie press release



